Avant Diagnostics, Inc. (OTC: AVDX) is a medical diagnostic technology company specializing in large panel biomarker screening. The company’s first test, OvaDx®, is being developed in conjunction with Arrayit Corporation (OTCQB: ARYC) as the market’s first large panel biomarker screening test for pre-symptomatic ovarian cancer. In preclinical research studies, OvaDx demonstrated high sensitivity and specificity for all types and stages of ovarian cancer – including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon reception of FDA 510(k) clearance for OvaDx, Avant intends to sell or license the innovative technology as a diagnostic test for women seeking greater wellness.
When commercialized, the market for Avant’s sophisticated microarray-based test is likely to be immense. According to statistics from the American Cancer Society, ovarian cancer ranks fifth in terms of cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. In 2015, it’s estimated that more than 21,200 women will receive a new diagnosis of ovarian cancer in the United States. For these women, early diagnosis can be pivotal to surviving the disease. If diagnosed in stage I, the five-year survivability rate of ovarian cancer is 90 percent, but that statistic falls to 70 percent if diagnosis occurs in stage II, further demonstrating the considerable market need for highly sensitive testing technology such as OvaDx.
Avant is led by a management team with decades of related industry experience. The company’s president and chief executive officer, Gregg Linn, has been with Avant since December 2012. Prior to serving in this position, Linn held similar positions at two firms specializing in providing strategic financial and business development advisory services to public and non-public businesses.
Moving forward, Avant will look to lean on its experienced management team in order to continue making progress toward the commercialization of its groundbreaking OvaDx diagnostic tool. In April, the company announced the engagement of DOCRO, Inc. to manage the preparation and submission of required data as necessary to obtain a 510(k) clearance for OvaDx as an aid in monitoring women diagnosed with ovarian cancer. For prospective shareholders, this progress could foreshadow an opportunity for considerable financial growth in the future.
For more information, visit www.avantdiagnostics.com
